Karen A. Graham, M.D.

E-mail:  Karen_Graham@med.unc.edu
Phone:  (919) 966-7088; (919) 929-2311

Education:

B.Sc. Honors; University of Guelph, Guelph, Ontario, Canada, 1987

M.Sc.; Pharmacology, University of Toronto, Ontario, Canada, 1990

M.D.; McMaster University, Hamilton, Ontario, Canada, 1993

Resident, Psychiatry (PGY1-2); McMaster University, Hamilton, Ontario, Canada, 1995

Resident, Psychiatry; University of North Carolina - Chapel Hill NC 2000

Summary Statement:

Dr. Graham works with Outreach And Support Intervention Services (OASIS) in Chapel Hill.  She also Co-Chair of Committee for the award-winning STEP Art Gallery, Brushes With Life, which features the work of artists who have been treated for psychiatric disorders at UNC Hospitals. 

Dr. Graham is currently Principal Investigator on two studies: The first investigating body mass index, body composition, resting energy expenditure, respiratory quotient and metabolic changes in patients following a switch from olanzapine, quetiapine or risperidone to aripiprazole; and the second is a double blind, placebo-controlled investigation of amantadine for prevention of weight gain in first episode adult psychotic patients beginning therapy with olanzapine.

Recent Representative Publications:

Book Chapter:
Graham KA , Lieberman JA. The Late Bloomer. Treatment Companion to the Dsm-IV-TR Casebook Robert L. Spitzer (Editor) American Psychiatric Press, 2004.

Peer Reviewed Journals:

1. Graham, KA, Hongbin Gu, Lieberman JA, Harp JB, Perkins DO: Double blind placebo controlled investigation of amantadine for weight loss in subjects who have gained weight during treatment with olanzapine. Am J Psychiatry In press

1. Graham KA, Perkins DO, Edwards LJ, Barrier RC, Lieberman JA, Harp JB: Effect of olanzapine on body composition and energy expenditure in first episode psychotic adults. Am J Psychiatry 162 (1):118-123, 2005.
2. Perkins DO, Lesserman J, Jarskog LF, Graham K, Kazmer J, Lieberman JA: Characterizing and dating the onset of symptoms in psychotic illness: the Symptom Onset in Schizophrenia (SOS) inventory. Schizophrenia Research 44:1-10, 2000.
3. Perkins DO, Leserman J, Graham K, Kazmer J, Jarskog F: The Symptom Onset In Schizophrenia (SOS) Scale: Determining the Onset of Prodromal and Psychotic Symptoms. American College of Neuropsychopharmacology , December 1997.
4. Jarskog LF, Perkins DO , Graham KA, Broadwell S, Regan JJ: Nerve Growth Factor Levels in Schizophrenia in Response to Stress. Biological Psychiatry , 1997.